UNSPSC 51111766: Vinblastine

This classification denotes a vinca alkaloid compound and vinca-site binding agent with the molecular formula C46H58N4O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5V9KLZ54CY, chemically known as 1h-indolizino(8,1-cd)carbazole-5-carboxylic acid, 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2h-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-, methyl ester, (3ar-(3aalpha,4beta,5beta,5abeta,9(3r*,5s*,7r*,9s*),10br*,13aalpha))- but generally known as vinblastine, which bears US NIH Compound Identifier 13342.

UNSPSC 51111766 Vinblastine (Commodity) shows minimal recent state and local procurement activity aligned to the code's pharmaceutical-product scope. The two most recent opportunities posted under this code in 2026 involve unrelated pharmaceutical products—an Illinois Department of Public Health piggyback award for antibiotics (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) through the MMCAP Infuse cooperative purchasing vehicle, and a Seminole County, Florida IFB for Naloxone and drug deactivation systems. Neither opportunity involves vinblastine itself, suggesting the code may be misapplied in the source data or that jurisdictions are routing pharmaceutical procurements through broader taxonomy or cooperative agreements rather than discrete commodity classifications.

The issuing bodies accessing state and local pharmaceutical supply chains include state health departments and county health authorities, typically through established cooperative purchasing consortiums and fixed-price IFB or award processes. The geographic spread in recent postings spans at least Florida and Illinois. Without evidence of active vinblastine-specific solicitations, the code does not surface as a meaningful procurement avenue under its nominal scope. Practitioners pursuing pharmaceutical supply contracts should monitor cooperative purchasing vehicles (such as MMCAP Infuse) and state health department procurement channels rather than tracking this specific commodity code; the actual buying appears concentrated in broader pharmaceutical warehousing and supply-chain aggregation structures.